A total of 401 patients with EGFR-mutant non–small cell lung cancer (NSCLC) beginning treatment with EGFR TKIs from September 1, 2019, to July 31, 2022, were retrospectively analyzed. This evidence concerns the gene EGFR and lung cancer.